Zogenix (ZGNX) Tops Q1 EPS by 2c

Zogenix (NASDAQ: ZGNX) reported Q1 EPS of ($0.86), $0.02 better than the analyst estimate of ($0.88). Revenue for the quarter came in at $2.7 million versus the consensus estimate of $4.23 million.

“Zogenix has a clear development pathway to regulatory submissions for ZX008 in the U.S. and Europe in Dravet syndrome,” said Stephen J. Farr, Ph.D., President and CEO of Zogenix. “With enrollment now complete in Study 1, our first Phase 3 trial, we look forward to the availability of top-line data in the third quarter of this year. We believe ZX008 has the potential to transform the lives of children and their families with Dravet syndrome. Beyond this indication, following the acceptance of our Investigational New Drug Application (IND) by the U.S. Food and Drug Administration (FDA), we are pleased to be in a position to initiate our Phase 3 clinical trial for ZX008 in Lennox Gastaut Syndrome (LGS) after we have the top-line data from Study 1.”

For earnings history and earnings-related data on Zogenix (ZGNX) click here.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• Altria Group (MO) Reports In-Line Q1 EPS, Offers FY24 EPS Guidance
• Mobileye (MBLY) misses estimates for Q1 earnings, revenue; shares slip